Drug Trial Radar · NCT00922779
A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C
Last checked: Nov 20, 2026Latest source record: Jan 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,661
Actual
Start
Jun 2002
Primary completion
Jun 2012
Study completion Jun 2012
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 17, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This single arm study will evaluate the safety and tolerability of ribavirin in combination with PEGASYS in patients with chronic hepatitis C. Patients will receive ribavirin 800mg, or 1000-1200mg po daily, according to HCV genotype and body weight (\< and \>75kg)in combination with PEGASYS 180micrograms sc weekly. The anticipated time on study treatment is 3-12 months, and the target sample size is \>500 individuals.
Conditions
- Hepatitis C, Chronic
Interventions
peginterferon alfa-2a [Pegasys]Drug
180micrograms sc weekly for 12-48 weeks
ribavirinDrug
800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Non-Serious Adverse Events (AEs) And Serious Adverse Events (SAEs)Time frame: From signing of informed consent up to end of study (up to Week 72)
Locations
93 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Arkhangelsk, Russia
Site not named
Barnaul, Russia
Site not named
Barnaul, Russia
Site not named
Blagoveshchensk, Russia
Site not named
Cheboksary, Russia
Site not named
Chelyabinsk, Russia
Site not named
Chelyabinsk, Russia
Site not named
Chelyabinsk, Russia
Site not named
Cherepovets, Russia
Site not named
Chita, Russia
Site not named
Irkutsk, Russia
Site not named
Irkutsk, Russia
Site not named
Irkutsk, Russia
Site not named
Izhevsk, Russia
Site not named
Kazan', Russia
Site not named
Kemerovo, Russia
Site not named
Kemerovo, Russia
Site not named
Kemerovo, Russia
Site not named
Khabarovsk, Russia
Site not named
Khabarovsk, Russia
Site not named
Khabarovsk, Russia
Site not named
Kirov, Russia
Site not named
Krasnodar, Russia
Site not named
Krasnodar, Russia
Site not named
Krasnodar, Russia
Site not named
Krasnoyarsk, Russia
Site not named
Krasnoyarsk, Russia
Site not named
Lipetsk, Russia
Site not named
Makhachkala, Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.